Global incidence and outcome of testicular cancer

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 417-427

  Shanmugalingam, Thurkaa ^a   Soultati, Aspasia ^b   Chowdhury, Simon ^b   Rudman, Sarah ^b   Van Hemelrijck, Mieke ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Global; Incidence; Mortality; Testicular cancer

Indexed keywords

AGE; ARTICLE; ASIA; AUSTRALIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CHINA; COLOMBIA; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; MALE; NEW ZEALAND; PACIFIC ISLANDS; POLAND; POPULATION RESEARCH; SPAIN; SWEDEN; TESTIS CANCER; UNITED KINGDOM; UNITED STATES; WESTERN HEMISPHERE; WORLD HEALTH ORGANIZATION;

EID: 84885911099     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S34430     Document Type: Article

References (41)

1. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005;115(5): 822-827.
2. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1151-1159.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBO-CAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No.10. Lyon, France: International Agency for Research on Cancer. 2010 v2.0. Available from: http:// globocan.iarc.fr. Accessed February 1, 2013.
4. Richiardi L, Bellocco R, Adami HO, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2157-2166.
5. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754-765.
6. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011;60(2):374-379.
7. Wanderås EH, Tretli S, Fosså SD. Trends in incidence of testicular cancer in Norway 1955-1992. Eur J Cancer. 1995;31A(12):2044-2048.
8. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118(12):3099-3111.
9. Trama A, Mallone S, Nicolai N, et al; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. Eur J Cancer. 2012;48(2):159-169.
10. WHO Mortality Database [database on the Internet]. Geneva, Switzerland: World Health Organization. Available from: http://www.who.int/healthinfo/ statistics/mortality/en/index.html. Accessed November 16, 2012.
11. Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Cancer Incidence in Five Continents, Volumes I to IX: IARC CancerBase No. 9. Lyon, France: International Agency for Research on Cancer. 2010. Available from: http://ci5.iarc.fr. Accessed November 16, 2012.
12. Kim HJ, Fay FM, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3): 335-351.
13. Beiki O, Granath F, Allebeck P, Akre O, Moradi T. Subtype-specific risk of testicular tumors among immigrants and their descendants in Sweden, 1960 to 2007. Cancer Epidemiol Biomarkers Prev. 2010;19(4): 1053-1065.
14. Hemminki K, Mousavi SM, Brandt A, Ji J, Sundquist J. Histology-specifc risks in testicular cancer in immigrants to Sweden. Endocr Relat Cancer. 2010;17(2):329-334.
15. Turnbull C, Rahman N. Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour. Int J Androl. 2011;34(4 Pt 2):e86-e96; discussion e96-e97.
16. Greene MH, Kratz CP, Mai PL, et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer. 2010;17(2):R109-R121.
17. Gu Y, Runyan C, Shoemaker A, Surani A, Wylie C. Steel factor controls primordial germ cell survival and motility from the time of their speci-fication in the allantois, and provides a continuous niche throughout their migration. Development. 2009;136(8):1295-1303.
18. Vega A, Baptissart M, Caira F, Brugnon F, Lobaccaro JM, Volle DH. Epigenetic: a molecular link between testicular cancer and environmental exposures. Front Endocrinol (Lausanne). 2012;3:150.
19. Brokken LJ, Lundberg-Giwercman Y, Rajpert De-Meyts E, et al. Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer. Mol Cell Endocrinol. 2012;351(2):279-285.
20. Chia VM, Li Y, Quraishi SM, et al. Effect modification of endocrine disruptors and testicular germ cell tumour risk by hormone-metabolizing genes. Int J Androl. 2010;33(4):588-596.
21. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C. Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr Relat Cancer. 2010;17(1):17-25.
22. Kristiansen W, Andreassen KE, Karlsson R, et al. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Hum Reprod. 2012;27(5):1525-1535.
23. Davis-Dao CA, Siegmund KD, Vandenberg DJ, et al. Heterogenous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types. Carcinogenesis. 2011;32(8):1238-1243.
24. Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer. 2012;118(17):4290-4297.
25. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 1993;341(8857):1392-1395.
26. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16(5):972-978.
27. Meeks JJ, Sheinfeld J, Eggener SE. Environmental toxicology of testicular cancer. Urol Oncol. 2012;30(2):212-215.
28. McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. Nat Rev Urol. 2012;9(6):339-349.
29. Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. Western and eastern European trends in testicular cancer mortality. Lancet. 2001;357(9271): 1853-1854.
30. Ugwumba FO, Aghaji AE. Testicular cancer: Management challenges in an African developing country. S Afr Med J. 2010;100(7):452-455.
31. Vlayen J, Vrijens F, Devriese S, Beirens K, Van Eycken E, Stordeur S. Quality indicators for testicular cancer: a population-based study. Eur J Cancer. 2012;48(8):1133-1140.
32. Singhera M, Lees K, Huddart R, Horwich A. Minimizing toxicity in early-stage testicular cancer treatment. Expert Rev Anticancer Ther. 2012;12(2):185-193.
33. Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35):4677-4681.
34. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol. 1988;6(10):1597-1603.
35. Keskin S, Ekenel M, Başaran M, Bavbek S. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy. Am J Clin Oncol. 2012;35(4):369-372.
36. Ruf CG, Linbecker M, Port M, et al. Predicting metastasized seminoma using gene expression. BJU Int. 2012;110(2 Pt 2):E14-E20.
37. Mohamed GH, Gelfond JA, Nicolas MM, et al. Genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis. Urolog y. 2012;80(2):485.e1-485.e5.
38. Fosså SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specifc survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29(8):963-970.
39. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657.
40. Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-1365.
41. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010;102(15):1114-1130.